The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples

Grillo, Federica; Fassan, Matteo; Ceccaroli, Chiara; Giacometti, Cinzia; Curto, Monica; Zagonel, Vittorina; Ceppa, Paola; Nitti, Donato; Castoro, Carlo; Fiocca, Roberto; Rugge, Massimo; Mastracci, Luca

doi:10.1593/tlo.12334

Cited by 45 publications

(41 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В кишечном типе HER2-позитивные опухоли выявлены в 21,4% случаев, в диффузном типе -в 6,1%, в смешанном -15,9%. Эти данные согласуются с результатами исследований ряда других авторов, прове-денных на других выборках [4,5,11]. Частота случаев с по-ложительным HER2-статусом в нашем исследовании прямо коррелировала со степенью дифференцировки РЖ.…”

Section: результаты и обсуждениеunclassified

“…5). По мнению ряда авторов [10][11][12], различия в определении HER2-статуса в основном связа-Рис. 1.…”

Section: )unclassified

“…Распределение HER2-позитивных карцином в за-висимости от локализации опухоли и степени ее диффе-ренцировки (%). ны с гетерогенностью опухоли, поэтому в биопсийный материал могут попадать участки опухоли, не полностью отражающие ее свойства [11]. Повторный анализ качества биопсий нашего материала, в которых были выявлены расхождения, показал, что в двух из них количество ку-сочков было 3-5 (меньше рекомендованных 6-8).…”

Section: )unclassified

“…[10], -в 91,8%, в исследовании F. Grillo и соавт. [11] -89%, в работе S. Watson и соавт. [12] (крупное клиниче-ское исследование GERCOR, проведенное на 228 пациен-тах) -в 95,6%.…”

unclassified

See 3 more Smart Citations

Comparative study of the determination of the HER2 status in gastric cancer in the biopsy and intraoperative specimens

Lé¹,

IuIu²,

IIu³

et al. 2014

Arkh. patol.

View full text Add to dashboard Cite

Section: результаты и обсуждениеunclassified

“…5). По мнению ряда авторов [10][11][12], различия в определении HER2-статуса в основном связа-Рис. 1.…”

Section: )unclassified

unclassified

See 2 more Smart Citations

Comparative study of the determination of the HER2 status in gastric cancer in the biopsy and intraoperative specimens

Lé¹,

IuIu²,

IIu³

et al. 2014

Arkh. patol.

View full text Add to dashboard Cite

“…Clinicians can choose biopsy or excision specimens for HER2 testing of patients with metachronous metastases. However, only a few studies have addressed the uniformity (or lack thereof) of HER2 IHC results obtained from endoscopic biopsies versus surgically excised material, and the relevant clinicopathological factors predicting different results in biopsy and excision specimens have not been investigated [11][12][13][14]. To address this issue, we conducted HER2 testing of paired endoscopic biopsy and surgical excision specimens from 180 patients with gastric cancer.…”

Section: Introductionmentioning

confidence: 99%

HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance

Huang

Lee

et al. 2014

Gastric Cancer

View full text Add to dashboard Cite

Background Inclusion of trastuzumab in chemotherapy regimens is advantageous for patients with advanced or metastatic gastric cancer who overexpress HER2. Therefore, accurate assessment of HER2 status in tumor tissue is critical when weighing treatment options. Methods We examined HER2 expression in 180 paired endoscopic biopsy and surgical excision specimens of gastric cancers via immunohistochemistry (IHC). Equivocal IHC results (IHC 2?) were resolved by HER2 fluorescence in situ hybridization (FISH). The relationships of several clinical and pathological features with discordant HER2 results in paired specimens were determined. Results Fourteen biopsy specimens and surgical specimens (7.8 %) were HER2-positive. Discordant HER2 IHC scores were observed in 90 paired specimens (50 %) and 8 paired specimens (4.4 %) had discordant results. The kappa coefficients for an HER2 diagnostic algorithm were 0.264, 0.339, and 0.690 for IHC scores, IHC categories, and final results, respectively (p \ 0.001). Discordant HER2 results were significantly associated with discordant tumor differentiation in the paired biopsy and excision specimens (p = 0.01). Intratumoral heterogeneity did not predict HER2 discordance. There was no association between HER2 discordance and the number of biopsy tissue fragments (p = 0.764). Conclusions Hofmann's HER2 scoring system is a fairly reliable tool for evaluating HER2 status in biopsy and excision specimens. Discordant HER2 results in paired specimens were observed in a small percentage of gastric cancers. Testing all available specimens should be considered in order to eliminate discrepancies, especially when discordant tumor differentiation is observed.

show abstract

TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer

Shinmura

Kiyose

Nagura

et al. 2013

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples

Abstract: The predictive value of HER2 IHC in biopsies is high. FISH analysis should be considered for IHC score 2+ and 1+ biopsy cases. Approximately 8% of cases will not be accurately predicted by biopsy evaluation.

Cited by 45 publications

References 30 publications

Comparative study of the determination of the HER2 status in gastric cancer in the biopsy and intraoperative specimens

Comparative study of the determination of the HER2 status in gastric cancer in the biopsy and intraoperative specimens

HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance

TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer

Contact Info

Product

Resources

About